TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07030257: Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Sponsor: Tasca Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,138,830

Rescue Site Savings

+$746,130

Unlock Full NCT07030257 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07030257 Rescue Dossier →